SANOFI-AVENTIS has entered
into an agreement with Oramed
Pharmaceuticals which will see it
supply Oramed with recombinant
human insulin which will be used
in Oramed’s US clinical trials.
“Oramed’s oral delivery
technology together with sanofiaventis’
capabilities to produce
insulin on a large scale supports
Oramed’s efforts to conduct
clinical development of Oramed’s
oral insulin capsule in the growing
diabetes market in the US,” said
Nadav Kidron, Oramed’s ceo.The above article was sent to subscribers in Pharmacy Daily's issue from 08 Jul 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Jul 10
THE Independent Pharmacies of Australia Group (IPA) revealed strategic plans for 2025 at its Impact Partnership Forum and held its awards gala in Melbourne last week.
THE Tasmanian Government announced on Fri new tighter regulations restricting the sale of nicotine-containing vapes to patients with a prescription from a GP or nurse practitioner.
STRONG growth in Australia has helped MedAdvisor Solutions achieve robust results for FY24, with a revenue increase of 24.6% on the previous corresponding period to $122.1 million.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.